Kidney Disease

ERA 2024 – The ZENTITH CKD trial demonstrated a reduction of 27% in UACR with the combination of the endothelin A receptor antagonist zibotentan plus dapagliflozin compared with dapagliflozin alone in patients with CKD. What are findings of an analysis of effect on cardiometabolic markers?

This summary is based on the presentation of Philip Ambery (Gothenburg, Sweden) at the ERA Congress 2024 – Cardiometabolic benefits of low dose zibotentan and dapagliflozin 10 mg in the ZENITH-CKD stu...

ERA 2024 – In a post hoc analysis of EMPA-KIDNEY, treatment with empagliflozin reduced the risk of kidney disease progression or CV death in patients with CKD compared with placebo, irrespective of frailty or multimorbidity.

This summary is based on the presentation of Kaitlin Mayne, MD (Oxford, UK) at the ERA Congress 2024 – The impact of multimorbidity on the effects of empagliflozin in chronic kidney disease (CKD): exp...

ERA 2024 – Previous analyses of CVOTs have suggested that GLP-1RAs reduce kidney-related outcomes in patients with T2D, but data of dedicated kidney outcomes trial were lacking. At the ERA Congress 2024 findings of the FLOW trial with semaglutide were presented.

This summary is based on the presentation of Peter Rossing, MD (Copenhagen, Denmark), Richard Pratley, MD (Orlando, FL, USA), Vlado Perkovic, PhD (Syndey, Australia), Kenneth Mahaffey, MD (Palo Alto...

In a secondary analysis of PARADIGM-HF, the clinical benefits of sacubitril/valsartan versus enalapril on CV and renal outcomes were mostly consistent in patients with HFrEF across KDIGO risk categories.

This summary is based on the publication of Chatur S, Neuen BL, Claggett BL, et al. - Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure. J Am Coll...

The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) has been published, updating the previous KDIGO 2012 guideline.

The KDIGO 2024 guideline aims to assist clinicians in the management of patients with CKD, both adults and children. However, this guideline is not focused on people receiving dialysis and kidney tran...

In a prespecified analysis of DAPA-CKD among patients with CKD and albuminuria, dapagliflozin resulted in a placebo-adjusted reduction in systolic blood pressure (BP) reduction of ~3 mmHg. Treatment benefits were apparent across a range of baseline BP levels.

This summary is based on the publication of Heerspink HJL, Provenzano M, Vart P, et al. - Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. Am Heart J. 2024 Feb...

In the FLOW trial, treatment with semaglutide reduced the risk of the primary composite endpoint of kidney disease progression, or death from kidney disease or CVD by 24% in people with T2D and CKD.

The headline results from the FLOW trial have been announced. Treatment with semaglutide 1.0 mg reduced the primary composite endpoint of kidney disease progression, or death from kidney disease or CV...

In a phase 2 trial, 14-week treatment with BI 690517, in addition to RAASi therapy, dose-dependently reduced albuminuria compared with placebo in CKD patients, either as monotherapy or in combination with empagliflozin. The drug’s safety profile was deemed acceptable.

This summary is based on the publication of Tuttle KR, Hauske SJ, Canziani ME, et al. - Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease...

In a prespecified secondary analysis of EMPA-KIDNEY, empagliflozin reduced progression of CKD in different subgroups of patients with CKD, including in patients with little albuminuria.

This summary is based on the publication of EMPA-KIDNEY Collaborative Group - Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY ...

In a post-hoc FIDELITY analysis, early albuminuria reduction induced by finerenone appeared to mediate a large proportion of renal outcomes and a modest proportion of CV outcomes in patients with CKD and T2D.

This summary is based on the publication of Agarwal R, Tu W, Farjat AE, et al. - Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation A...

AHA 2023 The AHA has developed new equations for CVD risk assessment with optional equations that include cardiovascular-kidney-metabolic (CKM) health and the endorsement of the life course perspective on prediction and prevention of CVD.

Presented at the AHA Scientific Sessions 2023 by: Sadiya Khan, MD - Chicago, IL, US

Intr...

AHA 2023 In the registry-based randomized clinical trial DAPI-MI, dapagliflozin improved cardiometabolic outcomes in patients with acute MI and impaired LV systolic function without diabetes or chronic HF compared with placebo.

Presented at the AHA Scientific Sessions 2023 by: Stefan James, MD, PhD - Uppsala, Sweden

Introduction and me...

A study estimated the lifetime benefit of SGLT2 inhibitor and nonsteroidal MRA combination treatment versus conventional therapy. Treatment with canagliflozin plus finerenone reduced the risk of adverse renal outcomes by 50% in patients with T2D and CKD compared with conventional therapy only.

14-week phase II data showed a significant reduction of albuminuria with a novel selective aldosterone synthase inhibitor on top of empagliflozin in patients with CKD.

14-week phase II data showed a significant reduction of albuminuria of up to 39.5% with a novel selective aldosterone synthase inhibitor on top of empagliflozin in patients with CKD...

In a real-world Swedish cohort study among HFrEF patients, MRA use was not associated with a higher risk of adverse renal outcomes, mortality, and hospitalization at 1 year compared with nonuse. This also applied to those with severe CKD.

The American Heart Association has published a scientific statement on the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome.

The American Heart Association (AHA) published a summary on the evidence and fundamental gaps related to the science, screening, prevention, and management on cardiovascular-kidney...